Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
GAB2
REST API REST API
Homo sapiens
GAB2 is differentially expressed in 296 experiments: 107 organism parts: bone marrow, cerebellum, ... (105 more);, 168 disease states: normal, acute promyelocytic leukemia, ... (166 more);, 88 cell types 387 cell lines 33 compound treatments and 71 other conditions.
Synonyms KIAA0571
Orthologs GAB2 (Danio rerio)   ENSGALG00000017264 (Gallus gallus)   ENSBTAG00000002922 (Bos taurus)   dos (Drosophila melanogaster)   gab2 (Xenopus laevis)   ENSCAFG00000004782 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, protein binding, cytoplasm, positive regulation of cell proliferation, transmembrane receptor protein tyrosine kinase signaling pathway, SH3/SH2 adaptor activity, phosphatidylinositol-3,4,5-trisphosphate binding, positive regulation of mast cell degranulation, phosphatidylinositol-3,4-bisphosphate binding, osteoclast differentiation, phosphatidylinositol-mediated signaling, transmembrane receptor protein tyrosine kinase adaptor activity
InterPro Term Pleckstrin_homology
UniProt Accession Q9UQC2, E9PJ26, E9PJE2
Search EB-eye ENSG00000033327
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (41 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
T84
2
E-GEOD-1474, E-MTAB-37
Jurkat
2
E-MEXP-2197, E-GEOD-1880
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
KG1
2
E-MTAB-37, E-GEOD-24147
381 more value(s).


Cell type

studied in E-GEOD-22529, E-TABM-40, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, ... (45 experiments)

Factor Value U/D Experiments
mononuclear cell
2
E-GEOD-6053, E-MEXP-66
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
mononuclear
2
E-GEOD-13987, E-GEOD-26672
whole blood
2
E-GEOD-3026, E-MTAB-25
CD4+ T cell
1
2
E-MTAB-25, E-MTAB-24, E-AFMX-5
testis - germ cell
1
E-AFMX-5
82 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (60 experiments)

Factor Value U/D Experiments
glioblastoma
1
3
E-GEOD-4290, E-MTAB-37, E-GEOD-4412, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-7307
choriocarcinoma
2
E-MTAB-62, E-MTAB-37
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
chronic lymphocytic leukemia
1
2
E-GEOD-2466, E-GEOD-6691, E-MTAB-37
162 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-1417, E-TABM-782, E-GEOD-5824, E-MEXP-1958, ... (25 experiments)

Factor Value U/D Experiments
HMB-PP (phosphoantigen)
1
E-MEXP-1601
1mM GDC-0941
1
E-GEOD-20719
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
Cxcl12
1
E-GEOD-7307
lipopolysaccharide
1
E-MEXP-1958
TGF
1
E-GEOD-15205
27 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
88 years
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-2171, ... (9 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-19246, E-GEOD-1563, ... (7 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-3140, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-7788, E-GEOD-22148, E-TABM-147, E-GEOD-21138, E-GEOD-3013 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-22593, E-GEOD-18736, E-TABM-868, E-GEOD-18005, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, E-GEOD-837, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276, E-GEOD-20194, E-GEOD-16716, E-GEOD-2748

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-1648, ... (29 experiments)

Infection
studied in E-MEXP-1274

Karyotype
studied in E-GEOD-12662

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-GEOD-1676, E-MEXP-1857, E-MEXP-1315, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7540, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.612 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM